Cabaletta Bio CABA 深 沪
等待开盘 09-24 09:30:00 美东时间
2.22
-0.280
-11.20%
华盛通- 最 高2.56
- 今 开2.53
- 成交量 867.72万股
- 最 低 2.19
- 昨 收 2.50
- 总市值 3.76亿
- 52周最高 4.23
- 市盈率 静 --
- 换手率 5.12%
- 52周最低 2.00
- 委 比 38.23%
- 总股本 1.70亿
- 历史最高 26.35
- 量 比 1.32
- 振 幅 14.80%
- 历史最低 0.59
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
09-02 01:15
Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted downbeat results for the second quarter. Cango reported quarterly losses of $1.99 per share which missed the...
09-01 20:02
三例死亡！诺华踩下CAR-T自免急刹车
近日，诺华因3例罕见的免疫效应细胞相关噬血细胞综合征（IEC-HS）死亡病例，紧急叫停八项自免临床试验；BMS则因常规监测中发现短暂且可逆的炎症事件，出于充分审...
09-01 16:31
Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio, a late-stage clinical biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases, announced its participation in several upcoming investor conferences in September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, the 2026 Cantor Global Healthcare Conference in New York on September 9, the Morgan Stanley 24th Annual Global Healthcare C...
09-01 12:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
08-14 22:46
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 53.42 percent increase over losses of $(0.73) per share from the same period last year.
08-13 19:34
Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis
Cabaletta Bio, Inc. ($CABA) announced an update on their ongoing clinical study...
06-26 00:30
Bending Spoons files for U.S. IPO
Bending Spoons, the parent company of AOL, Vimeo, and Eventbrite, has filed to go public in the U.S. with plans for an initial public offering this summer. The Milan-based tech company buys popular bu...
06-09 02:02
